COVID-19 Guidelines for Researchers
The Office of Research and Innovation continues to work with the campus leadership and community to establish guidance specific to research operations. The following information is intended to assist the campus research community in limiting the impact and potential risk associated with COVID-19. Please check back for updates or contact OR&I with any questions at email@example.com.
Last update: Augst 11, 2021
Reporting a Documented Case of COVID-19
All notifications should be reported to firstname.lastname@example.org.
COVID-19 Awareness Training
Click each agency for a full list of updates.
✔ Agency temporarily adjusted terms and conditions
X Agency has not temporarily adjusted standard terms and conditions or has not issued updated guidance
✔X Agency has adjusted some but not all conditions
|Agency||Possible deadline flexibility||Waiver for Notice of Funding Opportunities (NOFOs) Publication||No-cost extensions on expiring awards||Abbreviated continuation requests||Allowability of salaries and other project activities||Allowability of costs not normally chargeable to awards (ex: non-refundable travel costs)||Prior approval requirement waivers||Exemption of certain procurement requirement||Extension of financial and other reporting||Extension of closeout||Pre-award Costs|
|DOD - BR/RD||✔||✔||✔||✔||✔|
Funding Opportunities Related to COVID-19
American Heart Association
- AHA Rapid Response Grant COVID-19 and Its Cardiovascular Impact (March 30, 2020)
Biomedical Advanced Research & Development Authority
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement
Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.
Centers for Disease Control
- Centers for Disease Control COVID-19 Broad Agency Announcement
THIS IS AN IMMEDIATE CALL FOR WHITE PAPERS. Prior to submission of a white paper, offerors are strongly encouraged to contact the CDC BAA technical point of contact for the research topic/subtopic of interest. White papers must be received electronically by 3:00PM EST on March 25, 2020 in order to be considered for further evaluation.
Department of Defense
- Prototype Development to Combat Novel Coronavirus Disease COVID-19
The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19).
Department of Energy
- Asking for input on COVID-19 rapid research response involving DOE user facilities
DOE is encouraging the scientific community and others to consider research questions that underpin COVID-19 response and is requesting input on strategic, priority research directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure.
National Institute for Health Research
- Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak
This scheme provides travel and subsistence funding to support delivery of technical expertise in the global response to Covid-19. This service is not delivered to, or on behalf of, the Department of Health and Social Care (DHSC)/the National Institute for Health Research (NIHR) and does not constitute a contractual or service agreement, employer/employee or agent/principal relationship between any institution, body or person and the DHSC/NIHR.
National Institute of Allergy and Infectious Diseases
- Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive
Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030) (February 6, 2020)
The National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences are issuing this NOSI to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
- 2020 NIAID Omnibus Broad Agency Announcement
NIAID 2020 OMNIBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2020-1 contains five (5) distinct Research Areas, each with a specified closing date and time.
National Institutes of Health
- Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements
and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
- Notice of Special Interest (NOSI): Availability of Administrative Supplements and
Revision Supplements on Coronavirus Disease 2019 (COVID-19)
NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
- Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
- Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory
Mechanisms (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses.
- Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent
Supplement - Clinical Trial Optional)
The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.
- Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.
National Science Foundation
- Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)
This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge.
- Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research
on the Coronavirus Disease 2019 (COVID-19)
Before submitting a RAPID proposal or supplemental funding request in response to this DCL, investigators must first contact one of the cognizant OAC program officers listed.
Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.
- DCL: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation's and world's ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program.
United States Department of Agriculture
Other funding and research resources
- Novel Coronavirus Information Center
Elsevier's free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19
- Elsevier COVID-19 Clinical Toolkit
Open access to clinical resources and tools focused on the latest evidence-based practices for COVID-19 covering topics from symptom management to diagnosis, treatment and ongoing wellness.
- Infectious Disease Outbreak Research: Insights and Trends (on demand webinar)
Please join us for this webinar as Dr. Bamini Jayabalasingham explains how the research was conducted to uncover trends in outbreaks research, the various governmental bodies involved and the ways to identify health security research. Dr. Margaret Trexler Hessen will provide insight into how the research fits into the clinical context and why it matters.